We studied two patients with 3-methylglutaconic aciduria in order to determine the molecular defect. A new assay for 3-methylglutaconyl-coenzyme A (CoA) hydratase has been developed in which the substrate, [5-14Cj3-methylglutaconyl-CoA, was synthesized using 3-methylcrotonyl-CoA carboxylase purified from bovine kidney. In this assay the products of the reaction are isolated by reverse-phase high performance liquid chromatography and the rates of conversion from substrate are measured. The Michaelis constant for 3-methylglutaconyl-CoA in normal fibroblasts was 6.9 Mimol/liter. The mean activity of 3-methylglutaconyl-CoA hydratase in control fibroblasts was 495 pmol/ min per mg protein. In the two patients the values were 11 and 17 pmol/min per mg protein, or 2-3% of normal.
Introduction
3-Methylglutaconic aciduria is a recently described disorder of leucine metabolism, characterized by an abnormal organic acid profile in which there is excessive excretion of 3-methylglutaconic acid and 3-methylglutaric acid (1) (2) (3) (4) . Nine patients have been reported to have this disorder (1) (2) (3) (4) (5) (6) . Most of these patients (2, 3, 5) appeared normal for the first 4-9 nio oflife, then developed severe neurological degeneration. In two siblings (1) the phenotype was very different. Prominent clinical manifestations were limited to retardation of speech, and large quantities of 3-hydroxyisovaleric acid, as well as 3-methylglutaconic acid and 3-methylglutaric acid, were excreted in the urine. These compounds are all on the degradative pathway for leucine ( Fig. 1 ). In these patients the excretion of 3-hydroxy-3-methylglutaric acid (HMG)' was not elevated. Therefore, it has been postulated that the site of the enzyme defect is in the enzyme, 3-methylDr. Narisawa is on leave from the Department of Pediatrics, Tohoku University School of Medicine, Sendai 980, Japan. Address reprint requests to Dr. Sweetman.
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1. Abbreviations used in this paper: CoA, coenzyme A; 3-HB, 3-hydroxybutyric acid; HMG, 3-hydroxy-3-methylglutaric acid; HMG-CoA, 3 -hydroxy-3-methylglutaryl-CoA; HPLC, high performance liquid chromatography; id., inside diameter; MCC, 3-methylcrotonyl-CoA-carboxylase; 3-MG-CoA, 3-methylglutaconyl-CoA.
glutaconyl-coenzyme A (CoA) hydratase (E.C. 4.2.1.18) (7) . However, this has not previously been established. We have developed a new method for the direct assay of 3-methylglutaconylCoA hydratase (3-MG-CoA hydratase). We have studied fibroblasts derived from the two siblings described by Duran et al. (1) , and have documented a deficiency of 3-MG-CoA hydratase.
Methods
Materials. Adenosine-5'-triphosphate (ATP), NADH, 3-methylcrotonylCoA, 3-hydroxybutyrate dehydrogenase (Type IV), polyethylene glycol 6000, and DEAE cellulose were purchased from Sigma Chemical Co. (St. Louis, MO). Sephadex G-10, Sepharose 6B, and DEAE-Sephadex A-25 resins were obtained from Pharmacia Fine Chemicals (Piscataway, NJ). Hydroxylapatite (Bio-Gel HTP) was purchased from Bio-Rad Laboratories (Richmond, CA) and PM 10 ultrafiltration membranes were obtained from Amicon Corp. (Danvers, MA). NaH'4CO3 (9.2 mCi/mmol) was purchased from New England Nuclear (Boston, MA). All other reagents were of the highest purity available. The reverse-phase high performance liquid chromatography (HPLC) column employed has been described by DeBuysere and Olson (8) .
Purification of 3-methylcrotonyl-CoA carboxylase (MCC Preparation of[5-"C]3-MG-CoA. The product of MCC is the trans isomer (E-form) of 3-MG-CoA (11) . That this is the isomer which is the substrate for 3-MG-CoA hydratase is indicated by the fact that E-3-MGCoA is the product ofthe reverse reaction, the dehydration of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) catalyzed by 3-MG-CoA hydratase (12) . The purified MCC was used for the enzymatic synthesis of [5- '4C]E-3-MG-CoA from NaH'4CO3, 3-methylcrotonyl-CoA, and ATP. Purified MCC (-0.025 U) was added to 3-MG-CoA hydratase assay. Fibroblasts derived from two siblings with 3-methylglutaconic aciduria (1) and control subjects were cultured in Eagle's minimal essential medium with 10% fetal calf serum. The cells were harvested by trypsinization, pelleted by centrifugation, and washed with Tris-buffered saline. Lymphocytes were isolated from whole venous blood by density gradient centrifugation (14) . Fibroblast or lymphocyte pellets were suspended in 50 mmol/liter Tris-HCI buffer, pH 7.5, containing 0.75 mmol/liter Na2EDTA (_5 X 106 cells/ml). The cell suspensions were lysed while chilled in an ice bath by sonic disruption for 2 X 10 s (28 W) with a 60-s pause between bursts using a Sonifer Cell Disruptor Model W-185 (Heat Systems Ultrasonics, Inc., Farmingdale, NY). separations were performed at room temperature and a flow rate of0.44 ml/min, and 1-min fractions were collected. Radioactivity was determined by liquid scintillation counting with 5 ml of fluor. Studies on the separation ofthe substrates and products as acyl-CoA esters by reverse-phase HPLC (8) showed that there was a small amount of isomerization of the substrate E-3-MG-CoA to Z-3-MG-CoA. The Z-isomer coeluted with HMG-CoA, the product of 3-MG-CoA hydratase. Therefore, the acylCoA substrates and products were hydrolyzed with base to the acids, and the reverse-phase HPLC conditions were modified to separate the free acids. The base hydrolysis caused considerable isomerization of the free 3-methylglutaconic acid.
Results
The assay of 3-MG-CoA hydratase utilized as substrate [5- Fig. 2 shows reverse-phase HPLC chromatograms ofreaction mixtures for the assay of 3-MG-CoA hydratase. In control fibroblast lysates there were significant radioactive peaks of[4C]3-hydroxybutyric acid (3-HB) and ['4C]3-hydroxy-3-methylglutaric acid (HMG), whereas in these areas essentially no activity was detectable in the assay blank, which lacked cell lysate. In the assay offibroblasts from patient 1 with 3-methylglutaconic aciduria, no peaks of radioactivity were found in the areas of 3-hydroxybutyric acid and HMG.
The activity of 3-MG-CoA hydratase was calculated as the sum of the isotope in the products 3-hydroxybutyric acid and HMG and expressed as pmol/min per mg protein. The activity of the enzyme in fibroblast sonicates was proportional to the time ofincubation up to at least 90 min (Fig. 3 A) and to protein concentration up to at least 150 Ag protein per assay (Fig. 3 B) .
In lymphocyte sonicates enzyme activity was proportional to the time of incubation up to at least 60 min and to protein concentration up to at least 90 ,ug protein per assay.
The kinetic properties of the enzyme in fibroblast and lymphocyte lysates were determined. 3-MG-CoA hydratase activity in fibroblasts from three different controls followed very similar curves (Fig. 4 A) as a function of 3-MG-CoA concentration. The total activity of 3-MG-CoA hydratase in control fibroblast sonicate did not vary greatly with changing pH from pH 6.0 to 8.0 (Fig. 5) , although there was an optimum at pH 7.0 to 7.5. The proportion of isotopes in HMG was much greater at pH below 7.0, whereas above 7.0 the proportion of total isotope found in 3-hydroxybutyric acid increased appreciably.
On the basis of the data obtained the standard assay was developed and incubations were hydratase in lysates prepared from fibroblasts ofthe two patients with 3-methylglutaconic aciduria and five controls are shown in Table I 
Discussion
We have developed a new method for the assay of 3-MG-CoA hydratase. In this assay the substrate was [5-'4C]3-MG-CoA synthesized in the reaction catalyzed by 3-methylcrotonyl-CoA carboxylase purified from bovine kidney. The products of the hydratase reaction were isolated, their isotope content determined, and the sum of the products formed from the precursor were the measure of the activity of the enzyme. The reaction was linear with time and enzyme content. Km values for 3-methylglutaconyl-CoA in normal human fibroblasts and lymphocytes were -6.9 and 9.4 ,gmol/liter, respectively.
Using this method, the activity of 3-MG-CoA hydratase was determined in fibroblasts from two patients with 3-methylglutaconic aciduria. A marked deficiency of enzyme activity was found in the two siblings, which provided direct evidence for a deficiency of the hydratase in these patients. Defects in all eight Table I enzymes involved in leucine degradation have now been reported.
The patients studied had a phenotype different from other patients in whom 3-methylglutaconic aciduria has been described (2-6). The similarities of the siblings we have studied indicate that this is the clinical picture of 3-MG-CoA hydratase deficiency. Both had retardation of speech development (1). In one this was the only abnormality. His older brother was also slow in motor development, having walked first at 2 yr of age, and had a short attention span. He had had an unexplained episode of unconsciousness which lasted nearly a day. He responded to an 18-h fast with symptomatic hypoglycemia and a metabolic acidosis. Fasting did not produce hypoglycemia in his sibling. 3-MGCoA hydratase deficiency is likely to be an autosomal recessively transmitted disorder. There was no known consanguinity of the parents of our patients. The assay developed should be suitable for the detection ofheterozygosity, but fibroblasts on the parents have not been available for study. Two siblings reported from Sweden had a slowly progressive encephalopathy, but the amounts of 3-methylglutaconic acid excreted in the urine were considerably smaller than in the patients we studied with 3-MGCoA hydratase deficiency. Two other infants reported from Sweden (3) had a similar progressive neurologic degenerative disease. We have studied the activity of 3-MG-CoA hydratase in fibroblasts from three patients with a similar clinical picture (4, 5) and found it to be normal (6) . Thus, the neurological degenerative form of 3-methylglutaconic aciduria does not appear to be due to a primary deficiency of 3-MG-CoA hydratase.
